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Welcome to the 3rd issue of the Journal of Medicines 
Development Sciences. Like previous issues it contains 
articles covering the entire process of drug develop-
ment from target identification to drug registration. 
The development of new medicinal products is cha-
racterized by a high rate of attrition at various stages, 
often due to safety problems. The use of efficient tox-
icological tests allowing early identification of safety 
issues is an appealing strategy to improve the effi-
ciency of drug development. This new concept of pre-
dictive toxicology is explained in a comprehensive 
way by Atienzar et al. and illustrated by many exam-
ples. 
P2Y receptors are a family of G protein-coupled 
receptors responsive to nucleotides released from cells 
in response to various stimuli. The P2Y12 receptor is 
so far the only member of that family that constitutes 
the target of medicinal products : inhibitors of platelet 
aggregation used as antithrombotic agents (clopido-
grel, prasugrel…)[1]. In the 2nd issue of the journal, it 
was shown that the company CERENIS has developed 
agonists of the P2Y13 receptor that could stimulate 
HDL uptake by hepatocytes and thereby increase the 
Reverse Cholesterol Transport[2]. In the present issue, 
Robaye et al. present another possible therapeutic ap-
plication: the use of P2Y6 agonists as vaccination ad-
juvants, based on their action on antigen-presenting 
dendritic cells.  
One way to foster the development of new medi-
cinal products is to boost the efficiency of clinical re-
search. In the 1st issue Silva et al. have described the 
ACRES initiative to build up a global system for clin-
ical research excellence[3]. In the present issue Elyse 
Summers describes another initiative: the AAHRPP 
accreditation of clinical research centers.  
Following previous articles on Africa[4] and Ko-
rea[5], two articles in this issue analyze trends in drug 
development in the Asia-Pacific region and Brazil 
respectively. Interestingly it appears that in both China 
and Brazil, long delays in the review and approval of 
clinical trials and new drug applications have been a 
frustration for biopharmaceutical companies. Both 
countries have now issued new guidances intended to 
accelerate the process and thereby increase their at-
tractiveness to biopharmaceutical companies. 
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